Apart from age, other determinants of EM identified in our study include features related to a more aggressive disease presentation (e.g., hypercalcemia, renal impairment, and anemia), high disease burden (e.g., ≥60% bone marrow plasma cells, thrombocytopenia, low albumin, and elevated β2-microglobulin), high-risk cytogenetics, and characteristics reflecting the patients’ physical condition (e.g., WHO performance status 3–4). This evidence concerns the gene HLA-G and Thrombocytopenia.